264 related articles for article (PubMed ID: 11464870)
1. Distribution of natural antibody against human neuroblastoma among children with or without neuroblastoma.
Fukuda M; Nozaki C; Ishiguro Y; Horibe K
Med Pediatr Oncol; 2001 Jan; 36(1):147-8. PubMed ID: 11464870
[TBL] [Abstract][Full Text] [Related]
2. Natural antibody against neuroblastoma among Japanese children with or without neuroblastoma.
Fukuda M; Nozaki C; Ishiguro Y; Horibe K
Cancer; 1999 Nov; 86(10):2166-70. PubMed ID: 10570448
[TBL] [Abstract][Full Text] [Related]
3. A novel metastatic animal model reflecting the clinical appearance of human neuroblastoma: growth arrest of orthotopic tumors by natural, cytotoxic human immunoglobulin M antibodies.
Engler S; Thiel C; Förster K; David K; Bredehorst R; Juhl H
Cancer Res; 2001 Apr; 61(7):2968-73. PubMed ID: 11306475
[TBL] [Abstract][Full Text] [Related]
4. Initial characterization of the apoptosis-inducing receptor for natural human anti-neuroblastoma IgM.
David K; Heiligtag S; Ollert MW; Teppke M; Vogel CW; Bredehorst R
Med Pediatr Oncol; 2001 Jan; 36(1):251-7. PubMed ID: 11464898
[TBL] [Abstract][Full Text] [Related]
5. Human natural immunoglobulin M antibodies induce apoptosis of human neuroblastoma cells by binding to a Mr 260,000 antigen.
David K; Ollert MW; Vollmert C; Heiligtag S; Eickhoff B; Erttmann R; Bredehorst R; Vogel CW
Cancer Res; 1999 Aug; 59(15):3768-75. PubMed ID: 10446994
[TBL] [Abstract][Full Text] [Related]
6. [Natural human IgM-antibodies in neuroblastoma therapy: preliminary findings of a phase I/II clinical trial].
Schmitt C; David K; Hiller J; Schrum J; Bredehorst R; Vogel CW; Löliger C; Erttmann R
Klin Padiatr; 1999; 211(4):314-8. PubMed ID: 10472569
[TBL] [Abstract][Full Text] [Related]
7. High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international neuroblastoma staging system Stage II and III neuroblastoma with MYCN amplification.
Laprie A; Michon J; Hartmann O; Munzer C; Leclair MD; Coze C; Valteau-Couanet D; Plantaz D; Carrie C; Habrand JL; Bergeron C; Chastagner P; Défachelles AS; Delattre O; Combaret V; Bénard J; Pérel Y; Gandemer V; Rubie H;
Cancer; 2004 Sep; 101(5):1081-9. PubMed ID: 15329919
[TBL] [Abstract][Full Text] [Related]
8. Prognostic influence of minimal residual disease detected by flow cytometry and peripheral blood stem cell transplantation by CD34+ selection in childhood advanced neuroblastoma.
Cai JY; Tang YJ; Jiang LM; Pan C; Chen J; Tang JY
Pediatr Blood Cancer; 2007 Dec; 49(7):952-7. PubMed ID: 17514736
[TBL] [Abstract][Full Text] [Related]
9. Neuroblastoma in adolescents: the Italian experience.
Conte M; Parodi S; De Bernardi B; Milanaccio C; Mazzocco K; Angelini P; Viscardi E; Di Cataldo A; Luksch R; Haupt R
Cancer; 2006 Mar; 106(6):1409-17. PubMed ID: 16475209
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of efficacy of treatment for 30 children with neuroblastoma].
Sun XF; Liu DG; Su YS; Lin TY; Chen XQ; He YJ
Ai Zheng; 2003 Dec; 22(12):1343-5. PubMed ID: 14693065
[TBL] [Abstract][Full Text] [Related]
11. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
[TBL] [Abstract][Full Text] [Related]
12. [Hepatopathy in patients with stage 4S neuroblastoma].
Claviez A; Hero B; Schneppenheim R; Berthold F
Klin Padiatr; 1996; 208(4):221-8. PubMed ID: 8926687
[TBL] [Abstract][Full Text] [Related]
13. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study.
Rudnick E; Khakoo Y; Antunes NL; Seeger RC; Brodeur GM; Shimada H; Gerbing RB; Stram DO; Matthay KK
Med Pediatr Oncol; 2001 Jun; 36(6):612-22. PubMed ID: 11344492
[TBL] [Abstract][Full Text] [Related]
14. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK
J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154
[TBL] [Abstract][Full Text] [Related]
15. Neuroblastoma.
Meir HM; Balawi I; Nayel H; Yousef MK; Badawood S; Al-Mobarak M
Saudi Med J; 2001 Aug; 22(8):674-80. PubMed ID: 11573111
[TBL] [Abstract][Full Text] [Related]
16. Induction of Ab3 and Ab3' antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma.
Cheung NK; Guo HF; Heller G; Cheung IY
Clin Cancer Res; 2000 Jul; 6(7):2653-60. PubMed ID: 10914706
[TBL] [Abstract][Full Text] [Related]
17. High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy.
Kushner BH; Cheung IY; Kramer K; Modak S; Cheung NK
Pediatr Blood Cancer; 2007 Apr; 48(4):430-4. PubMed ID: 16421906
[TBL] [Abstract][Full Text] [Related]
18. Neuroblastoma in adolescents and adults: the Memorial Sloan-Kettering experience.
Kushner BH; Kramer K; LaQuaglia MP; Modak S; Cheung NK
Med Pediatr Oncol; 2003 Dec; 41(6):508-15. PubMed ID: 14595707
[TBL] [Abstract][Full Text] [Related]
19. Experience of the Izmir Pediatric Oncology Group on Neuroblastoma: IPOG-NBL-92 Protocol.
Olgun N; Kansoy S; Aksoylar S; Cetingul N; Vergin C; Oniz H; Sarialioglu F; Kantar M; Uysal K; Tuncyurek M; Kargi A; Aktas S; Bayol U; Karaca I; Arikan A; Balik E; Aktug T; Elmas N; Kovanlikaya A; Kinay M; Anacak Y; Degirmenci B; Burak Z
Pediatr Hematol Oncol; 2003; 20(3):211-8. PubMed ID: 12637217
[TBL] [Abstract][Full Text] [Related]
20. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.
Horibe K; Fukuda M; Miyajima Y; Matsumoto K; Kondo M; Inaba J; Miyashita Y
Med Pediatr Oncol; 2001 Jan; 36(1):203-4. PubMed ID: 11464885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
